HIV weight loss drug trial aims to cut inflammation
NCT ID NCT06935838
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests if tirzepatide, a weekly injection, can help overweight or obese people with well-controlled HIV lose weight and reduce chronic inflammation. Twelve adults will receive increasing doses over 12 weeks, with a 4-week safety follow-up. Researchers will measure changes in body weight, body composition, liver fat, and inflammatory markers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John A Burns School of Medicine
Honolulu, Hawaii, 96813, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home visits may boost heart health for pregnant women in nigeria
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Choice may boost HIV prevention: a trial tests offering multiple PrEP options to young women in kenya
- Ultrasound and blood markers may unlock personalized treatment for rare nerve disease
- Home care plus nutrition may cut post-hospital deaths in HIV — a trial puts it to the test
- Could a diabetes drug protect obese Teens' hearts?